EuroPCR 24: Ancillary SMART Trial Analyses
Dr Roxana Mehran (Mount Sinai Hospital, US) joins us to discuss the findings from an ancillary analysis of the SMART trial (NCT04722250).
The SMART trial is a prospective, multi-center, randomized controlled study that aims to investigate the valve safety and performance of self expanding as compared to balloon-expandable transcatheter aortic valve replacement (TAVR) in patients with small aortic annuli and severe symptomatic aortic stenosis. At select sites, a stress echocardiography sub-study also evaluated the performance of self expandable and balloon-expandable TAVR in this patient group, after exercise stress testing.
716 patients were enrolled in the trial, and were randomized on a 1:1 basis to receive TAVR with either a Medtronic self-expanding transcatheter aortic valve, or an Edwards balloon-expandable transcatheter heart valve.
Interview Questions:
-What is the reasoning behind this ancillary study?
-Could you tell us about the patient groups and data that were studied?
-What were your key findings?
-What is the implication of these findings on clinical practice?
-In short, what is your take-home message for clinicians?
-Where are the remaining knowledge gaps?
Recorded on-site at EuroPCR Congress, Paris, 2024.
Editor: Jordan Rance
Video Specialists: Dan Brent,
Interviewer: Liam O'Neill
Visit Radcliffe Cardiology: https://www.radcliffecardiology.com/
Visit Radcliffe Vascular: https://www.radcliffevascular.com/
This content is intended for healthcare professionals only.
Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.
Like us on Facebook: / radcliffecardiology
Follow us on X: https://x.com/radcliffeCARDIO